Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptor-positive, HER2-negative, intermediate-risk early breast cancer treated with Ribociclib (LEE- 011) in the adjuvant setting.
The advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4/6 proteins, which play a key role in cell proliferation) has improved treatment prospects for patients with metastatic breast cancer whose tumour cells express hormone receptors but not the HER2 protein (HR+/HER2-). The NATALEE study showed that the addition of ribociclib for three years to conventional adjuvant hormone therapy (i.e. after surgery) prolonged survival free of invasive disease (i.e. extending to surrounding tissues) in patients with early HR breast cancer+ /HER2-. Unlike other studies, NATALEE included a group of patients at intermediate risk of recurrence, usually treated with adjuvant chemotherapy before receiving hormone therapy. However, the benefit of adjuvant chemotherapy in these patients is uncertain. The hypothesis of the NoLEEta study is that by using the CDK 4/6 inhibitor, patients could avoid adjuvant chemotherapy and therefore be spared the side- effects associated with this chemotherapy, without reducing the efficacy of the treatment.
Objectives
The primary objective of NoLEEta is to demonstrate that the combination of ribociclib with hormone therapy is as effective as the same treatment preceded by adjuvant chemotherapy in patients with non-metastatic breast cancer.The secondary objectives are to evaluate the efficacy, safety and tolerability of the treatments and quality of life in the 2 groups of patients.
Primary endpoint of the trial
The primary endpoint of the trial is invasive breast cancer-free survival (iBCFS) (i.e. the average length of time patients live with their disease without signs of cancer recurrence).
Secondary endpoints of the trial
The efficacy of the treatment will also be assessed by the average length of time patients live with the disease without signs of spread to neighbouring tissues or other organs, and the time interval between the start of treatment and death, if this occurs during the study. The study will also assess patients' tolerance of treatment and quality of life.
Trial design
A phase III multicentre, randomised (patients are randomly assigned to the treatment arm) chemotherapy de-escalation trial designed to show that the addition of ribociclib for 3 years to hormonal treatment is as effective as the same treatment preceded by adjuvant chemotherapy in patients with non-metastatic breast cancer at intermediate risk of recurrence who have undergone surgery. Eligible patients will be enrolled in the experimental arm, where they will receive a combination of ribociclib and hormonal treatment, or in the control arm, where they will receive chemotherapy first, followed by a combination of ribociclib and hormonal treatment. Patients will remain in the trial for no more than 8.5 years after randomization.
Trial population
Adult patients (≥18 years) with invasive breast cancer at intermediate risk of recurrence. They must have undergone curative surgery, be able to receive chemotherapy, be in good general health with normal haematological, renal and hepatic function. They must not have received prior treatment with a CDK4/6 inhibitor or chemotherapy, have no active autoimmune disease or other serious uncontrolled diseases, and have no history of invasive cancer within 2 years prior to inclusion.
Interventions
After signing the consent form, patients will enter the pre-inclusion period (up to 28 days before the start of treatment), during which the investigator will carry out all the necessary tests to assess their eligibility. If patients are eligible, they will be randomly assigned to treatment:
- The experimental group will receive the ribociclib combination for 3 years and hormonal treatment for at least 5 years (consisting of aromatase inhibitors and, for pre-menopausal women, GnRH agonists).
- The control group will receive the same treatment with approximately 6 months of chemotherapy beforehand.
To receive the treatment, patients will have to go to hospital where, at each visit, the medical team will carry out medical examinations before administering the treatment, in order to assess the patient's general state of health and tolerance of the treatment. After stopping ribociclib treatment, patients will be followed up in hospital every 6 months until the end of the first 5 years of hormone therapy, and then once a year until the end of the trial.
Hospitals
-
Centre du sein Fribourg - Brustzentrum Freiburg
-
Clinique Générale-Beaulieu
-
Kantonsspital Aarau AG
-
Kantonsspital Baselland
-
Kantonsspital Winterthur
-
Les hôpitaux universitaires de Genève
-
Onkologie Bellevue
-
St. Claraspital AG